XTL Biopharmaceuticals has completed the acquisition of Psyga Bio, making psychedelic medicine its core business. This move gives XTL access to Psyga's advanced clinical pipeline based on psilocybin and derivatives, a licensed GMP manufacturing facility, and a proprietary intellectual property library of over 250 unique mushroom strains. The acquisition positions XTL to lead in the emerging psychedelic therapeutics market, supported by recent US regulatory acceleration for psychedelic drug approvals. The company plans multiple clinical trials and aims to capitalize on growing market potential for treatments of mental health disorders like depression and PTSD.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Bunker Hill Mining Corp. has appointed Bradley Barnett as permanent CFO and Mark Hayes as General Counsel to support its transition to commercial production at the historic Bunker Hill Mine in Idaho. The company also achieved an improved 'A' grade in...
Alaska Air Group is rated Buy with a $60 fair value, reflecting confidence that recent losses are due to temporary fuel cost shocks. Despite a $193 million loss in Q1 and suspended guidance, the airline's core business segments like loyalty programs,...
UnitedHealth Group reported a strong second-quarter net income of $5.48 billion, driven by a significant reduction in medical costs. The company lowered its medical care ratio to 86.7% from 89.4% year-over-year by exiting unprofitable markets and man...
Compagnie Financière Richemont SA reported strong Q1 2027 results, driven mainly by accelerating growth in its Jewellery segment, which accounted for about 89% of sales growth and achieved double-digit increases across all regions and channels for th...
